Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.
Nat. Rev. Endocrinol. 17, 135–149 (2021)
Obesity and impaired metabolic health are established risk factors for the non-communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease, neurodegenerative diseases, cancer and nonalcoholic fatty liver disease, otherwise known as metabolic associated fatty liver disease (MAFLD). With the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), obesity and impaired metabolic health also emerged as important determinants of severe coronavirus disease 2019 (COVID-19). Furthermore, novel findings indicate that specifically visceral obesity and characteristics of impaired metabolic health such as hyperglycaemia, hypertension and subclinical inflammation are associated with a high risk of severe COVID-19. In this Review, we highlight how obesity and impaired metabolic health increase complications and mortality in COVID-19. We also summarize the consequences of SARS-CoV-2 infection for organ function and risk of NCDs. In addition, we discuss data indicating that the COVID-19 pandemic could have serious consequences for the obesity epidemic. As obesity and impaired metabolic health are both accelerators and consequences of severe COVID-19, and might adversely influence the efficacy of COVID-19 vaccines, we propose strategies for the prevention and treatment of obesity and impaired metabolic health on a clinical and population level, particularly while the COVID-19 pandemic is present.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Review
Thesis type
Editors
Keywords
Insulin-resistance; Ketogenic Diet; Ketone-bodies; Visceral Fat; Risk; Coronavirus; Mechanisms; Infection; Glucose; Ketoacidosis
Keywords plus
Language
english
Publication Year
2021
Prepublished in Year
HGF-reported in Year
2021
ISSN (print) / ISBN
1759-5029
e-ISSN
1759-5037
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 17,
Issue: ,
Pages: 135–149
Article Number: ,
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
New York, NY
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502400-001
Grants
German Research Foundation
German Federal Ministry of Education and Research
European Innovative Medicines Initiative SOPHIA
Copyright
Erfassungsdatum
2021-02-08